0001104659-24-042744.txt : 20240402
0001104659-24-042744.hdr.sgml : 20240402
20240402202924
ACCESSION NUMBER: 0001104659-24-042744
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240402
DATE AS OF CHANGE: 20240402
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: PATEL DINESH V PH D
CENTRAL INDEX KEY: 0001120477
ORGANIZATION NAME:
STATE OF INCORPORATION: DE
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37852
FILM NUMBER: 24816564
MAIL ADDRESS:
STREET 1: C/O PROTAGONIST THERAPEUTICS, INC.
STREET 2: 521 COTTONWOOD DRIVE, SUITE 100
CITY: MILPITAS
STATE: CA
ZIP: 95035
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc
CENTRAL INDEX KEY: 0001377121
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 980505495
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
BUSINESS PHONE: (510) 474-0170
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Therapeutics Inc
DATE OF NAME CHANGE: 20130605
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Inc
DATE OF NAME CHANGE: 20061002
4
1
tm2410626-1_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-04-01
0
0001377121
Protagonist Therapeutics, Inc
PTGX
0001120477
PATEL DINESH V PH D
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
NEWARK
CA
94560-1160
1
1
0
0
President and CEO
1
Common Stock
2024-04-01
4
S
0
25000
28.31
D
549590
D
Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 20, 2023.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $27.69 to $28.77. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
/s/ Matthew Gosling, Attorney-in-Fact for Dinesh V. Patel, Ph.D.
2024-04-02